HCPCS Level II code J0567 bills for the administration of cerliponase alfa, a 1 mg dose of an enzyme replacement therapy used in specialized treatment protocols. This code is significant nationally because it represents a high-cost, specialized pharmaceutical therapy commonly administered in hospital outpatient departments, infusion centers, or specialty clinics. Accurate coding affects coverage determinations, prior authorization workflows, and hospital and clinic reimbursement for complex drug therapies.

Key payers in the scope of this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what J0567 denotes, the clinical context for cerliponase alfa administration, and the payer landscape that typically governs coverage and payment. The publication covers benchmarks and billing considerations, relevant policy updates affecting high-cost biologics, and clinical context that informs site-of-service and utilization patterns. Data on associated taxonomies, ICD-10 diagnoses, related codes, and detailed modifier use are noted where available; if specific items are not in the input, the summary indicates that data is not available.